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Abstract
Adenoviruses (Ads), especially HAdV-5, have been genetically equipped with tumor-restricted replication potential to
enable applications in oncolytic cancer therapy. Such oncolytic adenoviruses have been well tolerated in cancer patients,
but their anti-tumor efficacy needs to be enhanced. In this regard, it should be considered that cancer cells, dependent on
their tissue of origin, can differ substantially from the normal host cells to which Ads are adapted by complex virus-host
interactions. Consequently, viral replication efficiency, a key determinant of oncolytic activity, might be suboptimal in cancer
cells. Therefore, we have analyzed both the replication kinetics of HAdV-5 and the virus-induced transcriptome in human
bronchial epithelial cells (HBEC) in comparison to cancer cells. This is the first report on genome-wide expression profiling of
Ads in their native host cells. We found that E1A expression and onset of viral genome replication are most rapid in HBEC
and considerably delayed in melanoma cells. In squamous cell lung carcinoma cells, we observed intermediate HAdV-5
replication kinetics. Infectious particle production, viral spread and lytic activity of HAdV-5 were attenuated in melanoma
cells versus HBEC. Expression profiling at the onset of viral genome replication revealed that HAdV-5 induced the strongest
changes in the cellular transcriptome in HBEC, followed by lung cancer and melanoma cells. We identified prominent
regulation of genes involved in cell cycle and DNA metabolism, replication and packaging in HBEC, which is in accord with
the necessity to induce S phase for viral replication. Strikingly, in melanoma cells HAdV-5 triggered opposing regulation of
said genes and, in contrast to lung cancer cells, no weak S phase induction was detected when using the E2F promoter as
reporter. Our results provide a rationale for improving oncolytic adenoviruses either by adaptation of viral infection to
target tumor cells or by modulating tumor cell functions to better support viral replication.
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Introduction
Adenoviruses (Ads) are emerging cancer therapeutics based on
their potency to infect and lyse cancer cells, a process termed viral
oncolysis [1,2]. This regimen features a unique amplification effect
as infected tumor cells produce progeny viruses that spread
infection in the tumor. A further advantage is that the mode of
action of oncolytic Ads differs from conventional therapies, to
which cancer cells frequently develop resistance. Restriction of
virus replication to tumor cells is essentially required for the
application of Ads in cancer therapy. In this regard, the extensive
knowledge of Ad structure, genome organization and replication
cycle combined with technologies for Ad engineering facilitates the
rational development of oncolytic Ads [2,3]. Indeed, oncolytic
viruses with outstanding tumor selectivity have been engineered
based on the closely related HAdV-2 and HAdV-5. This was
achieved either by mutating gene functions that are complemented
in cancer cells, but not in normal cells, or by targeting the
expression of essential viral genes to tumor cells [1,2,4]. Several
clinical trials have demonstrated that such engineered Ads are well
tolerated in patients, but that their therapeutic potency needs
improvement [5,6]. In this context, the opportunity for rational
engineering of Ads is again a key advantage as it facilitates the
development of advanced oncolytic agents. Correspondingly,
studies to improve Ad entry into cancer cells or to insert
therapeutic genes into oncolytic Ads have been reported [2,7,8].
Adenoviral oncolysis necessitates efficient Ad replication in
targeted cancer cells. Previous work in the field has not adequately
considered that cancer cells, dependent on the tissue of origin, can
differ substantially from normal Ad host cells. Thus, the virus does
not come across the cellular environment it is adapted to by
comprehensive virus-host cell interactions. In consequence, Ad
replication, cell lysis and spread might be suboptimal. Specifically,
HAdV-2 and -5 are evolutionary adapted to replicate in epithelial
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therapy of a wide variety of tumor targets. Indeed, mutations of
HAdV-5 that increase virus replication and spread in tumor cells
have been reported [10–12]. One example is the deletion of
E1B19K, which has anti-apoptotic activity. Deletion of E1B19K
has resulted in strongly increased HAdV-5 replication and
oncolysis in lung cancer cells. However, reduced replication has
been reported in cancer cells derived from other tissues including
melanoma cells [11,13–15]. These observations again point at cell-
type dependence of Ad-host cell interactions and, consequently,
Ad replication efficiency: Differences in the apoptosis program-
ming between normal and cancer cells, but also between different
cancer cells most likely cause the different permissivity to E1B19K-
deleted HAdV-5.
As obligatory intracellular parasites Ads are dependent on the
cellular energy production and biosynthetic machinery. In fact,
Ads have implemented diverse and intricate molecular mecha-
nisms to establish conditions in the host cell that ensure efficient
virus reproduction. These are best studied for HAdV-2 and -5
([16,17] and references therein). Correspondingly, products of
early viral gene expression - besides providing proteins required
for replication of the viral genome - manipulate the cellular
environment to support virus replication by multiple mechanisms,
especially by direct and indirect modulation of cellular transcrip-
tion ([17–19] and references therein). The first viral gene
expressed during Ad infection is E1A, which encodes a family of
proteins resulting from alternative splicing. E1A proteins induce
the expression of further early Ad genes and manipulate
transcription of cellular genes directly or indirectly [20,21]. The
largest E1A protein (13S) contains a potent transactivation domain
that induces transcription when E1A interacts with DNA-binding
proteins. Both 13S and 12S E1A proteins bind to pRb, resulting in
the release of E2F transcription factors from pRb-E2F complexes.
The E2F proteins then activate transcription of viral and cellular
genes via E2F-binding sites ([17,19,22,23] and references therein).
E2Fs widely induce cellular genes involved in the S phase of the
cell cycle, which are also required for Ad genome replication.
Further transcriptional activities of E1A proteins are mediated by
interaction with a panel of cellular factors which inhibit or activate
transcription, for example histone acetylases ([17] and references
therein). Another Ad early protein, E1B55K, contains a strong
transcription repression domain. By binding to the p53 transacti-
vation domain it functionally switches p53 from a transcription
activator to a repressor [24]. Furthermore, E1B55K together with
E4ORF6 trigger degradation of p53 [25]. The resulting shut-off of
p53-responsive pro-apoptotic genes counteracts the induction of
apoptosis triggered by abnormal stimulation of the cell cycle by
E1A.
The outstanding knowledge of Ad infection has been gained by
extensive studies that were mostly performed with HAdV-2 or -5
in HeLa and other cancer cells and focused on individual Ad
genes [17]. Thus, Ad infection in its normal environment of
native host cells, e.g. primary epithelial cells of the respiratory
tract for HAdV-5, has been rarely studied (most of these studies
analyzed the selectivity of oncolytic Ads, see discussion). Note that
HeLa cells differ from the normal Ad host cells, as they are of
cervical cancer origin and have been extensively passaged.
Moreover, they contain human papilloma virus genes which
affect cell functions important for Ad replication. Studies that
investigate how individual Ad genes affect cellular functions do
not consider the complex network of virus-host interactions
during virus infections. In this regard, microarray technology
represents a powerful tool for genome-wide monitoring of
reprogrammed cellular gene expression during Ad infection.
Indeed, previous microarray studies have revealed that HAdV-2
and -5 infections target multiple cellular pathways [26–30]. These
studies have been performed with HeLa cells and primary
fibroblasts. How Ad infections modulate genome-wide gene
expression of their native host cells has not been investigated to
date. Consequently, a comparative analysis of Ad-induced gene
expression profiles of tumor cells versus native Ad host cells,
which is of interest for the development of oncolytic Ads, is not
available to date.
In this study we therefore explored how Ad infection of cancer
cells differs from Ad infection of their normal host cells. To this
end, we performed a comparative analysis of HAdV-5 replication
kinetics and lytic activity in primary bronchial epithelial cells, lung
squamous cell carcinoma cells and melanoma cells. We chose this
set of cells, as they represent normal HAdV-5 host cells, cells of
tumors derived from HAdV-5 host cells and tumor cells derived
from an unrelated cell type, respectively. We subsequently
performed genome-wide expression profiling of HAdV-5 infection
in normal bronchial epithelial cells and tumor cells. Cell type-
dependent differences in the HAdV-5-induced cellular transcrip-
tomes were assessed by bioinformatic analysis.
Results
Lytic potency and replication efficiency of HAdV-5 in
normal human bronchial epithelial cells and cancer cells
We first assessed whether the efficiency of HAdV-5 spread-
dependent cell lysis and replication differ between native HAdV-5
host cells and cancer cells. Primary human bronchial epithelial
cells (HBECs) were used in our study as they represent the native
HAdV-5 host cells of the respiratory epithelium most closely. They
were compared to lung cancer cells SK-MES-1, SW900 (both
squamous cell carcinoma), and A549 (adenocarcinoma), to
melanoma cells SK-MEL-28 and Mel624, and to further human
primary normal cells, namely fibroblasts and keratinocytes. In a
cytotoxicity assay, we observed that spread-dependent cell lysis by
HAdV-5 was similarly efficient in HBECs, SW900 and A549 cells,
but attenuated in SK-MES-1 cells and even more in the two
melanoma cell lines (Fig. 1A). Cytotoxicity of HAdV-5 for
keratinocytes was similar to HBECs, whereas no cell killing was
observed for primary fibroblasts at the time of measurement.
These results clearly show that lytic potency of HAdV-5 is cell
type-dependent and can be strongly reduced in cancer cells
compared with HBECs. Of note, reduced lytic potency of HAdV-
5 in SK-MEL-28 and Mel624 cells cannot be attributed to
inefficient viral cell binding and entry, because these cells showed
strong expression of the HAdV-5 receptor CAR (Fig. S1) and were
even more susceptible to transduction by a replication-deficient
HAdV-5 vector than HBECs, A549 and SW900 cells (Table S1).
This is clear evidence that reduced lytic activity of HAdV-5 in
melanoma cells is determined at a post-entry step of virus
replication. In contrast, fibroblasts lacked CAR expression and
were difficult to transduce. As cells were stained 8 days post-
infection, which allows for several rounds of virus replication, the
results of the cytotoxicity assay indicate differences in the efficacy
of HAdV-5 replication and spread between melanoma cells and
HBEC. Therefore, we next compared HAdV-5 replication in
HBECs, SW900 and SK-MEL-28 more directly by quantification
of infectious virus particle production during one round of
replication (Fig. 1B). Infectious virus particle production by
HBECs was .100-fold higher than for SK-MEL-28 at 36 h and
48 h post-infection. Virus titers peaked for HBEC at 48 h,
whereas they continued to increase until 72 h for SK-MEL-28,
when they peaked at a titer still lower than for HBECs. Infectious
HAdV-5-Induced Transcriptome: HBEC vs. Cancer Cells
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HBECs, but remained approx 10-fold lower. We conclude that
HAdV-5 replication is delayed in SK-MEL-28 cells compared
with HBECs and SW900 cells, which is in accord with the
cytotoxicity data.
Kinetics of viral gene expression and genome replication
of HAdV-5 in HBECs and cancer cells
We next investigated the kinetics of HAdV-5 replication in
HBECs and cancer cells in more detail by quantification of viral
gene expression and genome replication (Fig. 2). As these
experiments were used to define the time point of subsequent
gene expression profiling, they were performed with the
correspondingly standardized procedures, i.e. cells were cultured
in microarray growth media and infected with virus titers
resulting in 80% infection efficiency for each cell type (Table
S1). Onset of viral DNA replication was delayed for melanoma
cells (SK-MEL-28, 20 h; Mel624, 24 h) and SK-MES-1 cells
(20 h) compared with SW900 cells (16 h) and HBEC (16 h or
12 h, dependent on the donor) (Fig. 2B). Primary fibroblasts
showed a late (24 h), but primary keratinocytes an early (16 h)
onset of viral DNA replication. These differences in HAdV-5
replication kinetics between the cell types correlated well with
differences of viral lysis and infectious particle production (see
Fig. 1). Analysis of E1A mRNA expression kinetics revealed that
differences in onset of DNA replication between the cell types
Figure 1. Comparison of HAdV-5 cytotoxicity and replication efficiency in primary cells and tumor cell lines. (A) Cytotoxicity: Various
cell types were infected with either the wild type HAdV-5 (wt) or the replication-deficient control virus HAdV-5 CMV-gfp (gfp) at MOIs of 10
1 to 10
24
TCID50/cell. Cells were primary human bronchial epithelial cells (HBEC, cells from one of two donors giving similar results are shown), squamous cell
carcinoma of the lung (SK-MES-1, SW900), lung adenocarcinoma (A549), melanoma (SK-MEL-28, Mel624) primary human foreskin fibroblasts (HFF) and
primary human keratinocytes (PHK). After incubation for eight days, surviving cells were fixed and stained with crystal violet. Lung cells (left panels)
showed overall stronger cytotoxicity compared to melanoma cells (middle panels). (B) Replication: HBEC, SW900 or SK-MEL-28 cells were infected with
1 TCID50/cell of HAdV-5. After one hour incubation, inoculums were removed and cells were washed three times. Cells and supernatants were
harvested at indicated time points and infectious virus particles were quantified by determination of TCID50. Bars represent mean values of triplicate
infections and error bars standard deviations. Asterisks indicate statistical significance (p#0.05) of differences between SK-MEL-28 and HBEC as well as
SK-MEL-28 and SW900 (*), or between SW900 and HBEC (**). Increases of viral titers were significant (p#0.05) for HBEC until 48 h and for SK-MEL-28
until 72 h post infection. For SW900 viral titers showed no significant increase after 36 h (p=0.056 for 48 h versus 36 h).
doi:10.1371/journal.pone.0027934.g001
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SW900 and keratinocytes showed a rapid onset of E1A mRNA
expression reaching near-maximum levels at 8 h post-infection.
In contrast, for melanoma cells, SK-MES-1 and fibroblasts a
more slowly and continuous increase in E1A mRNA expression
was observed (Fig. 2A). The reason for the differences in E1A
expression between cell lines is unclear. Transient transfection
experiments with a reporter plasmid containing the first 557 bp
of the HAdV-5 genome did not reveal major differences in E1A
enhancer/promoter activity between cell types (Fig. S2). Late
viral gene expression mirrored the kinetics of viral genome
replication, as expected (Fig. 2C). We conclude that HAdV-5
replication and lysis are considerably more rapid in HBECs than
in melanoma cells. Replication and lysis in lung cancer cells is,
dependent on the cell line, rapid or intermediate. For other
primary cells, replication kinetics were dependent on the cell
type: epithelial keratinocytes showed rapid and mesenchymal
fibroblasts, as reported before [27,30], showed slow replication
kinetics.
Comparative analysis of HAdV-5-induced changes to
cellular gene expression in cancer cells versus HBECs
We next investigated whether cellular gene expression is
differently affected by Ad infection in cancer versus normal cells.
Therefore, we performed a comparative analysis of HAdV-5
infection-induced changes in transcriptomes of HBECs (2 different
donors), squamous cell lung cancer cells (SK-MES-1, SW900) and
melanoma cells (SK-MEL-28, Mel624). The cells were cultured
using standardized conditions and media (see Materials and
Methods for details) and were infected with HAdV-5 at titers
resulting in 80% transduction efficiency for each cell type or were
mock-infected. Cells were harvested at the time point of onset of
viral genome replication, because at that time key changes to the
cellular transcriptome in preparation of viral DNA replication
were expected. Furthermore, previous studies have shown less
changes at earlier time points for other cells [27,28,30]. By
choosing this time point for each cell type individually, according
to the kinetics shown in Fig. 2, we could adjust for differences in
viral replication kinetics between the cell types. Total RNA was
Figure 2. Viral gene expression and genome replication after HAdV-5 infection in primary cells and tumor cell lines. Human primary
cells (left panels) and tumor cell lines (right panels) were infected with HAdV-5 at titers resulting in 80% infection efficiency (see Fig. 1 for names of cell
types; HBEC d1, HBEC d2 are HBEC from different donors). Inoculums were removed after one hour incubation. Total RNA and DNA was harvested for
every indicated time point and was analyzed for E1A (A) and fiber (C) mRNA levels and for viral genome copies (B), respectively, by qPCR. Results of
representative experiments are shown; repetition experiments yielded identical time points for the onset of E1A and fiber mRNA expression and virus
genome replication. For HBEC d2, genome copy numbers were not determined at 20 h and 24 h, because of limited numbers of cells from this donor.
doi:10.1371/journal.pone.0027934.g002
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available on-line at the ArrayExpress database (accession number
E-MEXP-3125). During bioinformatic analysis gene expression in
uninfected samples was defined as steady state and compared to
gene expression levels in infected samples. Thereby, we deter-
mined the virus-induced cellular transcriptome, i.e. infection-
specific gene expression changes for each cell type individually
without creating a bias through inter-cell type variations by
different genetic backgrounds (see Materials and Methods for
details).
We found the strongest changes in gene expression by HAdV-5
infection in HBECs, followed by lung cancer cells, whereas gene
expression was much less affected by HAdV-5 infection in
melanoma cells (see also correspondence analysis in Fig. S3). Both
the numbers of cellular genes significantly regulated by HAdV-5
infection (Table 1) and the fold changes in gene expression
(ArrayExpress, E-MEXP-3125) were highest for HBECs and were
lowest for melanoma cells. These results correlate with the
replication efficiency of HAdV-5 for these cells: HBECs showed
both most efficient HAdV-5 replication and strongest virus-
induced gene expression, whereas for melanoma cells both
replication efficiency and virus-induced changes in gene expres-
sion were lowest.
As expression profiling of Ad infection of normal respiratory
epithelial cells has not been reported before, we first assessed the
HAdV-5-induced cellular transcriptome in HBEC. Our results
show the induction of genes involved in DNA replication and cell
cycle, chromatin organization, and nucleotide metabolism,
whereas genes involved in differentiation, regulation (mostly
negative) of proliferation, and cell death regulation were repressed
(Table 2 and Table S2).
Next, we compared gene expression signatures of HAdV-5
infection in HBECs and cancer cells by different bioinformatic
analyses. Hierarchical clustering of differentially regulated genes of
the five analyzed cell types highlighted two clusters of genes that
show opposing regulation in melanoma cells versus HBECs, i.e.
genes that are induced in HBECs, but repressed in one or both of
the melanoma cell lines (framed in Fig. 3A, magnified in Fig. S4).
Interestingly, the larger cluster shows a highly significant
accumulation of genes involved in DNA replication, nucleotide
metabolism, cell cycle regulation and DNA damage response
(Fig. 3B), which were also found in the smaller cluster (here
significance of accumulation was not reached because of the small
number of genes). Selected genes are listed in Table 3. These
cellular functions have been widely reported to be induced by Ad
infection [17] and these clusters contain several of the genes most
strongly induced in HBECs (see Table 2). Thus it is striking that
HAdV-5 fails to induce or frequently even represses these genes/
cellular functions in melanoma cells. The gene expression data
obtained by microarray analysis was validated by quantitative
PCR (Fig. S5). As a further bioinformatics approach to identify
cellular pathways most differentially regulated by HAdV-5
infection of melanoma cells versus HBECs, we performed
Ingenuity pathway analysis of the gene expression data. We
identified the G1/S transition regulatory network with key pro-S
phase genes (E2F, CCNE, CDK2, Cdc25A) induced in HBECs, but
repressed or not regulated in melanoma cells (Fig. S6). We
conclude that HAdV-5 infection of melanoma cells fails to induce
a panel of S phase genes involved in cell cycle regulation,
nucleotide metabolism and DNA replication and repair, which are
induced in the native HAdV-5 cells, HBEC.
Analysis of S phase induction by HAdV-5 infection using
the E2F-1 promoter as reporter
As gene expression profiling indicated that HAdV-5 fails to
induce genes critically involved in S phase processes in melanoma
cells, we next performed an independent biological assay to
investigate S phase induction by HAdV-5 infection. The E2F-1
promoter, which is strongly induced during S phase, was used as a
reporter for Ad-induced S phase entry [31]. HBEC, SW900, SK-
MES-1, A549, SK-MEL-28 and Mel624 cells were transfected
with luciferase reporter plasmids containing either the E2F-1
promoter or the constitutive SV40 promoter as control. Trans-
fected cells were subsequently superinfected with either HAdV-5
or with HAdV-5 CMV-gfp as E1-deleted, replication-deficient
control virus. Quantification of reporter gene expression (Fig. 4)
revealed that in lung cancer cells, infection with HAdV-5 induces
the E2F-1 promoter, but not the SV40 promoter, much stronger
than the replication-deficient virus control. In contrast, E2F-1
promoter induction by HAdV-5 infection was minimal or lacking
in melanoma cells. These results are in accord with our gene
expression profiling data and show that S phase induction by
HAdV-5 is efficient in HBEC, but poor in melanoma cells.
Discussion
Productive Ad infection is dependent on a cellular environment
that supports the different stages of the viral replication cycle.
Therefore, Ads have evolved strategies to manipulate the cellular
environment in host cells. Immediate early and early viral proteins
establish a complex network of interactions with host cell functions
in order to counteract host defenses and induce cellular pathways
necessary for replication of the viral genome. This includes the re-
programming of cellular gene expression. Here, we describe for
the first time the HAdV-5 infection-induced transcriptome for
HBECs, representing their native host cells. We first determined
the kinetics of HAdV-5 replication in HBECs, which is as follows:
E1A expression starts before 4 hours post-infection (h.p.i.) and
reaches a plateau at 8 h.p.i.; the first increase in viral genome and
fiber mRNA copies occurs at 8 or 12 h.p.i., dependent on the
donor, and infectious particle production reaches a plateau at
48 h.p.i.. This is followed by an efficient virus spread in the cell
monolayer, as observed by cytotoxicity assay after low titer
infection. Genome-wide expression profiling of HAdV-5-infected
HBECs at the onset of viral genome replication, when major
modifications to the host cell by early viral genes are expected,
revealed a significant increase in expression for 424 and a decrease
for 519 of 18,631 assessed genes. Thus gene repression was
prominent at this time point, even considering that it is more
difficult to detect than gene induction because of the half life of
mRNA present before infection. Genes involved in the cell cycle,
DNA replication, chromatin organization and nucleotide metab-
olism were accumulated in the upregulated gene population. This
Table 1. Number of genes regulated by HAdV-5 infection
(p,0.05) in HBEC, SW900, SK-MES-1, SK-MEL-28 and Mel624.
cell line
number of
regulated genes upregulated downregulated
HBEC 943 424 519
SW900 772 326 446
SK-MES-1 709 310 399
SK-MEL-28 314 112 202
Mel624 212 90 112
doi:10.1371/journal.pone.0027934.t001
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expression (11.5-fold), CCNE1 and CCNE2 (cyclin E1 and E2;
7.9- and 6.2-fold), RRM2 (ribonucleotide reductase M2; 5.2-fold),
CDC25A (3.5-fold), MCM2, 7 and 10 (3-, 3.3- and 3.3-fold), EXO1
(exonuclease 1; 3.1-fold), RFC3 and 4 (replication factor C3 and 4;
2.8- and 2.1-fold), PCNA (proliferating cell nuclear antigen; 2.2-
fold) and several histone, chromatin assembly factor and
centromere genes. These results are in accord with previous
studies which have established, though in other cell types, that S
phase induction in Ad-infected cells is required for viral replication
to proceed. The number of genes and induction rates that we
report might be even underestimated, as we did not synchronize
HBECs before infection in order to allow for a valid comparison to
cancer cells. Genes with activity in differentiation, negative
regulation of proliferation (including CDKN1A; 22.9 and
CDKN2B; 22.73), and cell death regulation were accumulated in
the repressed gene population (strongest repression was for
parathyroid hormone-like hormone, 16.1-fold). Of note, we did
not identify the accumulation of genes involved in immunity in the
upregulated gene pool.
HAdV-5 infection has been rarely investigated in normal
respiratory epithelial cells before. Several studies of oncolytic Ads
have compared primarily respiratory epithelial cells with tumor
cells in cytotoxicity and infectious particle production assays to
assess the selectivity and efficiency of virus mutants [32–39]. These
studies have shown that the production of infectious HAdV-5
particles in primary respiratory epithelial cells is efficient and peaks
around 48 h p.i. [37,39], which is in accord with our results.
Previous studies on expression profiling of Ad infection have
been performed with HeLa cells and human fibroblasts. For HeLa
cells, HAdV-2 infection at MOI 100 was reported to regulate 76,
60, or 382 genes more than 1.5-fold at 6 h, 10 h or 20 h.p.i.,
respectively (12,000 were analyzed at 6 h, 7,500 genes at 10 h and
20 h) [26,28]. Another study found 75 of 4,600 genes regulated
more than twofold by HAdV-5 at 24 h.p.i. of HeLa cells [40].
Whether the lower number of regulated genes in comparison to
HBECs in our study is due to the transformation of HeLa cells is
difficult to judge because of differences in methodology. In this
regard, our study showed a lower number of regulated genes for
both lung cancer and melanoma cell lines in direct comparison
with HBECs (see below). S phase genes were reported to be
induced by Ad infection in HeLa cells, including CDC25A (1.8 at
10 h), UNG (1.6) and histone genes [28], which we found also in
HBECs. Overlaps are also found in downregulated genes: MYC
(21.9 versus 22.4 in HBEC); THBS1 (thrombospondin-1; 22.6
versus 29.4 in HBEC); CAV2 (caveolin-2; 21.4 versus 24.0 in
Table 2. Gene annotations and genes significantly
accumulating in the top 100 up-regulated genes and gene
annotations significantly accumulating in the top 100 down-
regulated genes in HBEC (see Table S2 for genes significantly
accumulating in top 100 down-regulated genes in HBEC).
Upregulated GO-Terms
GO-Term/gene P-value/fold induction
protein-DNA complex assembly 2,2E-3
chromatin assembly 3,3E-3
DNA packaging 6,1E-3
chromatin assembly or disassembly 7,2E-3
H2BFS 9,29
HIST1H2 6,36
PRR6 5,05
HIST1H3 4,65
NAP1L5 4,44
HIST2H4 4,3
CHAF1B 3,93
DNA replication 6,4E-3
CCNE2 6,23
RRM2 5,2
CHAF1B 3,93
CDT1 3,7
CDC25A 3,45
MCM7 3,29
CDC45L 3,15
MCM10 2,88
nucleosome assembly 7,2E-3
nucleosome organization 1,0E-2
H2BFS 9,29
HIST1H2 6,36
HIST1H3 4,65
NAP1L5 4,44
HIST2H4 4,3
CHAF1B 3,93
DNA metabolic process 1,8E-2
CCNE2 6,23
RRM2 5,2
UNG 5,1
CHAF1B 3,93
CDT1 3,7
ALKBH2 3,6
CDC25A 3,45
MCM7 3,29
CDC45L 3,15
EXO1 3,12
MCM10 2,88
Downregulated GO-Terms
GO-Term P-value
regulation of cell proliferation 3,7E-8
blood vessel morphogenesis 3,7E-6
blood vessel development 9,9E-6
Downregulated GO-Terms
GO-Term P-value
vasculature development 1,0E-5
regulation of myeloid cell differentiation 4,4E-6
negative regulation of cell differentiation 1,8E-5
negative regulation of cell proliferation 5,3E-5
regulation of response to external stimulus 9,0E-5
response to mechanical stimulus 1,7E-4
regulation of apoptosis 1,8E-4
regulation of cell death 1,8E-4
doi:10.1371/journal.pone.0027934.t002
Table 2. Cont.
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of two days after infection of synchronized cultures with HAdV-2
at MOI 100 [27,29], or after infection with HAdV-5 at MOI 30
[30]. Zhao and co-workers investigated an array of 29,300 cDNA
clones and observed that 190 genes were upregulated and 265
genes were downregulated at 24 h.p.i., when viral genome
replication initiated [27]. This is lower in number but similar in
ratio to our findings in HBECs. Genes involved in cell cycle,
proliferation and DNA metabolism were upregulated including
several genes that we also identified in HBECs: CDC25A (3.2);
CCNE1 (2.3), CCNE2 (4.0); MCM3, 4, 5, and 6 (2.7, 4.7, 7.0, and
3.1); PCNA (7.3); EXO1 (2.9); RFC3 and 4 (2.4 and 2.5) and several
histones. Downregulated genes included differentiation factors,
cytoskeleton proteins and vesicle transport proteins with VEGF,
VEGFC, syntaxin 6, THBS1, collagen and claudin genes also found
in our study for HBECs. Miller and co-workers report 2,104 of
20,590 genes regulated more than twofold during the 2 day
interval investigated, two thirds of which were upregulated [30].
This study identified at the onset of viral replication in the
upregulated gene pool a significant accumulation of gene ontology
terms DNA replication, cell cycle, mitosis, M phase, DNA repair,
chromatin assembly, nucleosome assembly, RNA splicing, intra-
cellular transport, nucleocytoplasmic transport and ribosome
biogenesis, including several E2F-responsive genes that we also
found in HBECs. Overall our study identified a transcriptome for
HAdV-5 in HBECs with primarily S phase genes induced, which
correlates with previous observations in HeLa cells and fibroblasts.
Our study highlights that Ad replication can be attenuated in
tumor cells versus their native host cells. Specifically, we observed
a delay in E1A expression, onset of DNA replication and late gene
expression for HAdV-5 in tumor cells compared with HBEC. This
was most pronounced for Mel624 cells and least for SW900 cells.
Indeed the viral replication kinetics in melanoma cell lines
resembled those of fibroblasts, for which a slow Ad replication
cycle has been shown previously [29,30]. Spread-dependent lytic
activity of SW900 was similar to HBECs, but attenuated in SK-
MES-1 and even more so for the melanoma cell lines, in spite of
their higher susceptibility to transduction by HAdV-5 vectors. As
primary keratinocytes resembled HBECs with respect to HAdV-5
replication kinetics and spread-dependent cytotoxicity, our data
indicate that HAdV-5 replication is delayed in non-epithelial
versus epithelial cells. It is notable that HAdV-5 showed the most
rapid replication kinetics in HBEC followed by normal keratino-
cytes even when compared with epithelial lung cancer cell lines.
Hence, cellular transformation does not necessarily increase the
permissivity for Ad infection. From our data it can be concluded
that the timing of expression of the immediate early gene E1A is a
major determinant of cell type-dependent differences in HAdV-5
replication kinetics. The reasons for the cell type-dependent
differences in E1A expression remain to be determined. We
observed only minor differences in E1A enhancer/promoter
activity after transient transfection. Moreover, we previously
Figure 3. Hierarchical clustering of HAdV-5-induced gene
expression in HBEC and tumor cells. (A) Hierarchical clustering of
genes using Multi-Experiment Viewer (MeV 4.5.1) based on the approx.
1000 most significantly regulated genes (see Materials and Methods for
data filtration criteria). Clusters of genes showing opposing regulation
by HAdV-5 infection in HBEC versus melanoma cells are framed.
Magnifications of these clusters are presented in Fig. S4. (B) Lists of
genes within cluster 2 were subjected to gene ontology analysis using
the Database for Annotation, Visualization and Integrated Discovery
(DAVID; david.abcc.ncifcrf.gov). P-values of GO terms were corrected for
multiple testing using the Benjamini-Hochberg algorithm.
doi:10.1371/journal.pone.0027934.g003
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promoter does not increase lytic activity of HAdV-5 mutants in
SK-MEL-28 cells [41]. These results argue that cell type-
dependent differences in viral uptake, intracellular virus traffick-
ing, nuclear translocation of the virus genome and/or mRNA
stability might cause differences in E1A expression kinetics and
subsequent lytic activity of HAdV-5.
The considerable differences in the kinetics of early viral gene
expressionmake clearthatitisimportanttolookatthesamestageof
the viral replication cycle (rather than the same time point post
infection) when comparing host cell responses in different cell types.
Therefore, we performed our comparative analysis of the HAdV-5-
induced transcriptome at the onset of viral genome replication. The
number and fold induction rates of HAdV-5-induced cellular genes
was lower for tumor cell lines in the order SW900, SK-MES-1, SK-
MEL-28 and Mel624, which matched the kinetics and efficiency of
viral replication in these cells. In all cell types, less genes were
induced (36% to 45% of all regulated genes) than repressed. HAdV-
5-induced transcriptomes ofthe squamous cell carcinomalines were
more similar to HBEC than those of the melanoma cell lines. A
clear qualitative difference in the HAdV-5 induced transcriptome,
however, was observed between melanoma cells and HBEC,
represented by two clusters of genes repressed in melanoma cells,
but induced in HBEC. Such differences cannot be explained by the
delay in E1A expression in melanoma cells and must result from
other host cell-dependent factors. Especially genes involved in cell
cycle, DNA replication and DNA metabolism were accumulated in
the larger of the two clusters with high significance, indicating that
HAdV-5 fails to induce S phase genes in these melanoma cells. Also
the smaller cluster contained major S phase genes. However,
significance for accumulation of certain gene annotations was not
reached for this cluster due to its small size. Key player genes in cell
cycle control and DNA replication are included in these clusters:
E2F2 (21.5-fold in SK-MEL-28 versus 11.5-fold in HBEC), CCNE
(21.8/3.2), CDC45L (21.7/3.3), MCM2 (21.5/3.0), BLM (21.6/
2.7); note that maximal repression in SK-MEL-28 was 3.3-fold.
These expression profiling results are supported by a drastically or
even completely reduced induction of the E2F-responsive E2F-1
promoter, a reporter for S phase induction, in melanoma cells
compared with HBEC and lung cancer cells. As productive Ad
replication is dependent on the host cell entering S phase, these
differences are striking and likely to contribute to the delay in virus
replication and the reduced cytotoxicity of HAdV-5 in melanoma
cells. It is important to consider that in the chosen experimental
conditions,both HBECsand tumorcellswerecultured inlowserum
conditions and were proliferating. Thus melanoma cells should
enter S phase eventually. Still, HAdV-5 infection could accelerate S
phase entry in HBEC, but less so in melanoma cells. Furthermore,
virus-induced S phase entry might be of a different quality than S
phase entry within a normal cell cycle. Our efforts to identify, in a
larger panel of melanoma cells, individual virus-induced genes as
predictors of HAdV-5 oncolytic efficacy were not successful,
indicating that it is important to look at modifications of gene
networks rather than individual genes.
Table 3. Examples of genes with opposing regulation by HAdV-5 infection in HBECs versus melanoma cells.
gene symbol regulation in fold change expression after infection description
HBEC SW900/SK-MES-1 SK-MEL-28/Mel624
E2F2 11.5 1.9/1.7 21.5/(1.1) transcription factor
MCM7 3.3 1.3/(1.1) 21.5/(21.2) replication initiation
MCM10 3.3 1.2/1.2 21.4/(21.3) replication initiation
CENPM 3.3 1.3/(21.0) 21.5/(21.3) centromere protein
CDC45L 3.2 1.3/(1.0) 21.7/21.6 DNA replication factor
RAD51AP 3.1 21.4/(1.0) 21.7/21.7 DNA damage signaling
MCM2 3.0 1.4/(1.2) 21.5/(21.1) replication initiation
PFS2 2.9 1.5/(1.2) 21.4/(21.2) DNA replication factor
BLM 2.7 (1.2)/1.2 21.6/21.5 DNA helicase
TYMS 2.5 1.3/(1.0) 21.5/(21.2) thymidylate synthase
MCM5 2.2 (1.3)/(1.1) 21.6/(21.2) replication initiation
RFC4 2.1 (1.0)/(21.0) 21.5/21.4 DNA replication factor
PRIM1 2.1 (21.1)/(21.1) 21.9/21.9 primase
CDK2 2.1 1.4/(1.1) 21.3/21.7 kinase
POLQ 2.1 (21.1)/(1.1) 21.5/21.6 polymerase
BIRC3 1.5 (22.7)/(22.5) (1.0)/(1.1) apoptosis inhibitor
KIF2C 1.4 21.3/21.2 22.0/22.1 motor protein
TOP2A 1.4 21.4/21.5 22.5/22.2 topoisomerase
AURKB 1.4 (1.1)/(21.2) 22.1/22.2 kinase
CENPF 1.2 (21.1)/21.3 22.0/22.1 centromere protein
CDKN1A 22.9 (21.2)/(21.1) (1.2)/3.1 kinase inhibitor
EGR1 23.1 (1.0)/2.5 1.8/3.3 transcription factor
FOS 24.7 (1.0)/1.3 1.7/2.0 transcription factor
Numbers in parentheses: p.0.05; note that maximal up-/down-regulation is 11.5/216.1 for HBEC, 2.8/23.3 for SK-MEL-28 and 4.2/22.6 for Mel624.
doi:10.1371/journal.pone.0027934.t003
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molecular basis for both the delayed replication kinetics and the
differentgeneexpressionsignatureofHAdV-5infectioninmelanoma
cells compared with HBECs. Specifically, host factors should be
identified that differentially determine the following parameters:
kinetics of virus uptake, intracellular virus trafficking, nuclear
translocation of the virus genome, viral gene expression, and/or
viral manipulation of cellular gene expression. Such studies should be
extended to other tumor types because we hypothesize that especially
tumors of non-epithelial origin, like sarcomas or lymphomas, show
attenuated and/or delayed Ad replication. HAdV-5-induced tran-
scriptomes of these cells might reveal differences to HBECs which
could be either similar or distinct to our results for melanoma cells.
Ultimately, these efforts will provide opportunities for the develop-
ment of optimized oncolytic Ad therapies. Scenarios towards this end
include the genetic modification of oncolytic Ad genomes in order to
complement infection-supportive host cell activities that are lacking in
target tumor cells. Alternatively, such activities could be induced by
combination therapy, for example by addition of S phase-inducing
chemotherapies. Finally, directed evolution of Ads in tumor cells
might provide Ad mutants that establish an improved replication
efficacy and lytic activity based on accelerated E1A expression and/
or improved induction of S phase genes.
Materials and Methods
Cell culture
Human cell lines A549, SK-MEL-28, SW900 (all ATCC,
Manassas, VA), Mel624 (kindly provided by J. Schlom, Bethesda,
MD) and SK-MES-1 (cell repository German Cancer Research
Centre, Heidelberg) were all maintained in DMEM. 293 cells
(QBiogene, Heidelberg, Germany) were cultivated in RPMI1640.
HFF cells (primary human foreskin fibroblast; kindly provided by
M. Marschall, Erlangen, Germany) were cultivated in MEM
(Invitrogen, Karlsruhe, Germany). Media were supplemented with
10% heat-inactivated fetal bovine serum (FBS, PAA, Co ¨lbe,
Germany), 100 U/ml penicillin and 100 mg/ml streptomycin
(both Invitrogen). Primary HBEC (Lot 5092901.17 derived from
a 55 year old Caucasian male; Lot 7110910.11 originated from a
67 year old Caucasian male, both PromoCell, Heidelberg,
Germany) as well as PHK cells (primary human keratinocytes
from foreskin, kindly provided by N.S. Banerjee, University of
Alabama at Birmingham, Birmingham, AL) were cultivated in
complete Airway Epithelial Cell Growth Medium or Keratinocyte
Growth Medium 2 (both PromoCell), respectively. Cells were
grown at 37uC in a humidified atmosphere of 5% CO2. Media
were pre-warmed to 37uC in a water bath before use.
Figure 4. Analysis of S phase induction by HAdV-5 in HBEC and tumor cells using the E2F-1 promoter as reporter. (A) Luciferase
reporter gene plasmids containing E2F-1 or SV40 promoter fragments were transfected into the indicated cell lines. After 24 hours, cells were
infected with HAdV-5 (wt) or replication-deficient HAdV-5 CMV-gfp (gfp) at titers resulting in 80% infection. Luciferase activity was quantified twenty
hours post infection. Columns represent mean values of triplicate transfections/infections and error bars reflect standard deviation. Asterisks indicate
statistical significance for comparisons of HAdV-5 with HAdV-5 CMV-gfp (*p #0.05, ** p#0.01, *** p#0.001). (B) Different representation of data
shown in panel A: Fold change in promoter activity by HAdV-5 compared with HAdV-5 CMV-gfp.
doi:10.1371/journal.pone.0027934.g004
HAdV-5-Induced Transcriptome: HBEC vs. Cancer Cells
PLoS ONE | www.plosone.org 9 November 2011 | Volume 6 | Issue 11 | e27934Sub-cultivation of permanent cell lines for viral gene
expression, DNA replication, and microarray experiments
SK-MEL-28, Mel624, SW900 and SK-MES-1 were slowly
adapted to low serum conditions. Therefore, FBS content was
gradually reduced by mixing DMEM/10% FBS with rising
volumes of Melanocyte Growth Medium (SK-MEL-28, Mel624)
or Airway Epithelial Cell Growth Medium (SW900 and SK-MES-
1). Finally, cells were sub-cultivated in a mixture of one volume
DMEM/10% FBS and three volumes of Melanocyte Growth
Medium or Airway Epithelial Cell Growth Medium, respectively
(referred to as ‘‘microarray growth medium’’ herein). Frozen
aliquots of 1610
6/ml adapted cells were stored in liquid nitrogen
until further use. Prior to experiments, stocks were thawn in a
waterbath at 37uC for one minute, transferred to a 15 ml falcon
tube, and washed once in their respective microarray growth
medium. Afterwards, approx. 16,000 cells/cm
2 were seeded in
pre-warmed and CO2 equilibrated microarray growth medium.
The next day, medium was exchanged and cells incubated for
another day.
Recombinant adenoviruses
HAdV-5 is wild-type human adenovirus serotype 5. HAdV-5
CMV-gfp is an E1/E3-deleted gene transfer vector derived from
HAdV-5 that contains a CMV promoter-driven GFP gene.
Viruses were amplified by serial passages in A549 cells (HAdV-
5) or 293 cells (HAdV-5 CMV-gfp) and were purified by two
rounds of CsCl equilibrium density gradient ultracentrifugation.
Verification of viral genomes was performed by PCR. Physical
particle concentration (viral particle (vp)/ml) was determined by
OD260 nm reading; infectious viral particle titers were determined
by TCID50 assay on 293 cells.
Virus-mediated spread and cytotoxicity
To determine virus mediated cytotoxicity, 3610
4 cells were
seeded in 48 well plates. The following day, cells were infected in
200 ml DMEM/2% FBS containing Ads with concentrations from
0.0001–10 TCID50/cell in tenfold serial dilutions or were mock-
infected. The next day, 500 ml growth medium was added and
cells incubated until cytopathic effects could be observed in wells
containing a low viral inoculum. Cell lysis was documented by
aspirating the cell culture supernatants and staining of live cells by
addition of 100 ml of 2% crystal violet in 70% ethanol for
30 minutes at room temperature. Afterwards, plates were rinsed
twice in water to remove excessive dye, air-dried, and scanned to
obtain digital images.
Detection of CAR expression by FACS analysis
1610
6 cells were incubated on ice for 2 h with 14 mg/ml mouse
anti-CAR antibody RmcB (supernatant of hybridoma) or IgG1
isotype control, clone MOPC-21 (BioLegend, San Diego, CA) in
FACS buffer (PBS, 10% FCS and 0.01% NaN3). Cells were
washed twice with 1 ml FACS buffer and the incubated with
0.5 mg/ml anti-mouse-PE secondary antibody (BD Pharmigen,
San Diego, CA) for 1 h on ice. For final read-out, cells were
washed twice with 1 ml FACS buffer and resuspended in 600 ml
FACS buffer. Cells were analyzed by flow cytometry (FACSort,
BD Biosciences, Heidelberg, Germany) and data was evaluated
using FCS Express Version 3 software (De Novo Software, Los
Angeles, CA).
Determination of transduction rates in living cells
To determine transduction efficiency of HAdV-5 for each
individual cell type, 3610
4 cells were seeded into 24 well plates
and transduced after two days with various TCID50 titers of
HAdV-5 CMV-gfp diluted in 250 ml microarray growth medium
or DMEM/2% FBS (A549, PHK and HFF). After one hour at
37uC, medium was aspirated and replaced by 500 ml fresh
microarray growth medium or growth medium (A549, PHK and
HFF). Cells were harvested 48 hours post infection by trypsiniza-
tion and transgene levels in living cells were measured by flow
cytometry. To this end cells were washed twice in FACS washing
buffer DPBS/1% (v/v) FBS/0.01% (v/v) sodium azide and
collected by centrifugation at 225 g for 3 minutes. For staining
of dead cells, pellets were resuspended in 100 ml DPBS containing
a final concentration of 50 mg/ml propidium iodide and 100 mg/
ml RNAse A. After incubation at room temperature for
10 minutes, cells were further diluted in 200 ml FACS buffer
and analyzed immediately. All samples were analyzed on a
FACScan machine (BD Biosciences). Appropriate compensation
was set up for each experiment individually and data was recorded
for at least 10,000 events. Data was analyzed using FCS Express
Version 3 software.
DNA/RNA quantification by real-time PCR or microarray
analysis
For quantification of viral genome copy numbers or RNA
expression, 3610
4 cells were seeded in 24-well plates. For
microarray experiments samples were upscaled accordingly to 6
well plates. After two days, cells were infected in 250 (1000 for 6
well) ml microarray growth medium for one hour. Thereafter
inoculants were removed and samples were harvested at indicated
time points. Total genomic DNA was purified from cell lysates
with the QIAamp BloodMiniKit (Qiagen, Hilden, Germany);
RNA was purified with the RNeasy kit (Qiagen) following the
manufacturer’s instructions. For microarray analysis, QIAshred-
derH columns (Qiagen) were utilized to ensure higher lysate
homogeneity. For qPCR samples only, a digest with a RNAse free
DNAse Kits (Qiagen) was performed on the column or after
column purification according to the manual. Oligonucleotides
used for quantification of viral genomes, viral E1A, fiber and
hexon mRNA, cellular DNA and cellular RNA were described in.
Oligonucleotides for quantification of cellular genes were obtained
from Qiagen, Hilden and reconstituted in 1.1 ml TE buffer,
pH 8.0. Following primers were used: ACTB QT01680476, BLM
QT00027671, CCNE1 QT00041986, CD83 QT00069923,
CDC25A QT00001078, CDT1 QT00020601, CHAF1B
QT00012845, E2F2 QT00045654, E2F5 QT00062965, EGR1
QT00999964, FOS QT00007070, GAPDH QT01192646,
H2BFS QT00227199, HERC5 QT00007280, HES4
QT00208726, IRS2 QT00064036, MCM2 QT00070812,
MGC13057 QT00221347, PKMYT1 QT00013580, RFC3
QT00019243, TIPIN QT00054334, UNG1 QT00037912. Ade-
noviral genome copies, viral mRNA as well as cellular mRNA
expression levels were quantified by qPCR based on the detection
of Sybr Green on a 7300 Real Time PCR System (Applied
Biosystems, Darmstadt, Germany) using MicroAmpH 96 Well
Reaction Plates (Applied Biosystems). Each 25 ml sample con-
tained 16 Power SYBRH Green PCR Master Mix, 50 U/ml
reverse transcriptase (for RNA templates only), 20 U/ml RNAse
inhibitor (for RNA templates only), 10 mM of each primer or 16
Quantitect
TM primer mix and 20 ng template. For mRNA
quantification reverse transcription was carried out in plates at
48uC for 30 minutes directly before qPCR was performed with an
initial denaturation step of 10 min at 95uC, followed by 40 cycles
of 15 s denaturation at 95uC and 1 minute of annealing and
elongation at 60uC. At the end of each cycle, the fluorescence
emitted by the SYBR Green was measured. After completion of
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curve analysis from 60uCt o9 5 uC at 0.1uC/s with continuous
fluorescence monitoring to distinguish primer dimers and
unspecific amplicons from specific target gene products. Each
run further included negative controls as well as appropriate
standard curves whenever available. Standard curves for quanti-
fication of the copy numbers of viral genomes or viral mRNA was
diluted from pTG3602 plasmid (10
8,1 0
6,1 0
4 and 10
2 copies/ml).
Data was normalized with cellular genomic DNA (determination
of viral genome copy numbers) or cellular RNA (determination of
viral mRNA copy numbers) for each sample individually. Cellular
RNA was quantified using GAPDH oligonucleotides and 200, 20,
2 and 0.2 ng/ml of HeLa total RNA (Stratagene, Amsterdam, The
Netherlands). Cellular DNA was quantified using b-actin oligo-
nucleotides and 200, 20, 2 and 0.2 ng/ml human DNA isolated
from A549 cells as standard. Data was analyzed with the 7300
System SDS Software V1.4 (Applied Biosystems) and presented as
viral gene copy numbers and viral genome copy numbers
normalized with cellular genomic DNA or cellular RNA for each
sample individually. For cellular mRNAs, qgene was used to
obtain mean normalized expression values [42].
Burst assay
Experiments were carried out in triplicates using 3610
4 cells in
24 well plates but were otherwise identical as described for DNA/
RNA quantification. In addition, virus inoculum was removed one
hour post infection. Cells and supernatants were harvested at given
time points and viruses were released from cells by three freeze
thaw cycles. Cellular debris was removed by centrifugation and
infectious virus particles in supernatants were quantified by
TCID50 assays on 293 cells.
Probe Labeling and Illumina Sentrix BeadChip array
Hybridization
Total RNA from uninfected and infected cells was isolated.
Labeling and hybridizations were performed at the Genomics &
Proteomics Core Facility at the DKFZ. Briefly, sample quality was
assessed by gel analysis using the total RNA Nano chip assay on an
Agilent 2100 Bioanalyzer (Agilent Technologies, Berlin). Only
samples with a RNA index value greater than 8.5 were selected for
expression profiling. Biotin-labeled cRNA samples for hybridiza-
tion on Illumina Human Sentrix-8 BeadChip arrays (Illumina, San
Diego, CA) were prepared according to Illumina’s recommended
sample labeling procedure based on the modified Eberwine
protocol [43]. In brief, 250–500 ng total RNA was used for cDNA
synthesis, followed by an amplification/labeling step (in vitro
transcription) to synthesize biotin-labeled cRNA according to the
MessageAmp II aRNA Amplification kit (Ambion, Austin, TX).
Biotin-16-UTP was purchased from Roche Applied Science,
Penzberg, Germany. The cRNA was column purified according to
TotalPrep RNA Amplification Kit, and eluted in 60–80 mlo f
water. Quality of cRNA was controlled using the RNA Nano Chip
Assay on an Agilent 2100 Bioanalyzer and spectrophotometrically
quantified. Hybridization was performed at 58uC, in GEX-HCB
buffer (Illumina) at a concentration of 100 ng cRNA/ml, unsealed
in a wet chamber for 20 hours. Spike-in controls for low, medium
and highly abundant RNAs were added, as well as mismatch
control and biotinylation control oligonucleotides. Microarrays
were washed once in High Temp Wash buffer (Illumina) at 55uC
and then twice in E1BC buffer (Illumina) at room temperature for
5 minutes (in between washed with ethanol at room temperature).
After blocking for 5 min in 4 ml of 1% (w/v) Blocker Casein in
phosphate buffered saline Hammarsten grade (Pierce Biotechnol-
ogy, Rockford, IL), array signals were developed by a 10 minute
incubation time in 2 ml of 1 mg/ml Cy3-streptavidin (Amersham
Biosciences, Buckinghamshire, UK) solution and 1% blocking
solution. After a final wash in E1BC, the arrays were dried and
scanned.
Scanning and data analysis
Microarray scanning was done using a Beadstation array
scanner, adjusted to a scaling factor of 1 and PMT settings at 430.
Data was extracted for all beads individually, and outliers were
removed if .2.5 MAD (median absolute deviation). All remaining
data points were used for the calculation of the mean average
signal for a given probe, and standard deviation for each probe
was calculated. Data were loaded into the Multi-Conditional
Hybridization Intensity Processing System (M-CHiPS) [44] as
two-channel data with the infected samples as test and the
corresponding uninfected samples as reference channels, thereby
eliminating variations between different cell lines. Data was
subsequently normalized applying the locally weighted scatterplot
smoothing algorithm, LOWESS [45]. Genes with $1.5-fold
regulation and signal intensity .100 in at least one condition
were considered for downstream analysis. To filter for reproduc-
ible expression changes between replicates, outliers were excluded
using a very restrictive ‘min-max separation’ filter [46]. P-values
for each condition versus the control condition were calculated
using the empirical Bayes method in the LIMMA package
(Bioconductor) [47]. Data were visualised in a correspondence
analysis (CA) plot [48] allowing for simultaneous presentation of
experimental conditions and genes (Fig. S3). Differences between
conditions as well as genes associated with certain conditions are
represented by their relative position within the CA plot.
Differentially expressed genes were subjected to further analysis
by hierarchical clustering using the MultiExperiment Viewer 4.3.
Ingenuity Pathway Analysis (IPA; Ingenuity Systems, USA) and
DAVID [49,50] were used to find pathways or gene ontology
terms exhibiting a significant number of differentially regulated
genes. All gene expression data is MIAME compliant and the raw
data has been deposited in the MIAME compliant ArrayExpress
data base (http://www.ebi.ac.uk/arrayexpress) with accession
number E-MEXP-3125.
Reporter gene assay for S-phase entry
Twenty four hours prior transfection, 5–7.5610
4 cells (depend-
ing on the cell line) were seeded out in 0.5 ml of their respective
growth medium in 24 well plates. Cells reached approximately 60–
80% confluence on the next day and were transiently transfected
with a pGL3 luciferase reporter plasmid containing either the
SV40 promoter (Promega, Madison, WI) or the 2221/+60 bp
fragment of the human E2F-1 promoter in triplicates using
Lipofectamine
TM and PLUS
TM reagent (both Invitrogen) as
suggested by the manufacturer. Briefly, for every sample 0.5 mg
DNA was mixed with 100 ml OptiMEMH containing 0.5 ml
PLUS
TM reagent and incubated at room temperature for
15 minutes. Then, 2.5 ml Lipofectamine
TM was added and
samples mixed by vortexing. Following another 30 minutes
incubation time at room temperature, the transfection mix was
added directly to the cells over night for 24 hours. Then, cells were
infected with HAdV-5 or HAdV-5 CMV-gfp diluted in the
respective growth medium containing 2% FBS or no fetal calf
serum (HBEC). Inoculums were removed after one hour at 37uC
and cells grown in their normal growth media for twenty hours
before luciferase expression was quantified using the Luciferase
Assay System (Promega). Therefore, cells were washed once with
DPBS and lysed in 200 ml Reporter Lysis buffer. After incubation
for at least 30 minutes at 280uC, lysates were thawed at room
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Luciferase Assay substrate and immediately measured in a
FluoroskanAsentFL (Thermo-Scientific, Braunschweig, Germany).
Cells devoid for luciferase expression were used as negative
controls to determine nonspecific background.
Statistical analysis
Differences between indicated groups were analyzed using the
Student’s t test. For microarray data, P-values for each condition
versus the control condition were calculated using the empirical
Bayes method in the LIMMA package (Bioconductor) [47]. P-
values for genes of microarray experiments and gene ontology
terms were corrected for multiple testing using the Benjamini-
Hochberg algorithm [51]. P-values of ,0.05 were considered
statistically significant.
Supporting Information
Figure S1 Expression of HAdV-5 receptor CAR on SK-
MEL-28, Mel624, A549 and HFF cells. Detection of CAR
expression by flow cytometry after staining of cells with anti-CAR
antibody RmcB (black line) or isotype control (grey).
(TIF)
Figure S2 Reporter gene assay of E1A promoter activity
in HBEC, SW900, SK-MES-1, SK-MEL-28 and Mel624.
Cells were transfected with luciferase reporter gene plasmids.
Plasmids contained either no promoter (pGL3-basic, negative
control), the E1A promoter (pGL3-E1A), the strong CMV
promoter (pGL3-CMV), or the weak human thymidine kinase
promoter (pGL3-hTK). Luciferase activity was quantified 48 hours
post transfection and expressed as relative light units. Columns
represent mean values of triplicate transfections and error bars
reflect standard deviation; p-values were calculated for compar-
isons of the E1A and CMV promoter and for comparisons of the
E1A and hTK promoter using the Student’s t-test (* p#0.05,
** p#0.01).
(TIF)
Figure S3 Correspondence analysis of HAdV-5 infec-
tion-induced transcriptomes of HBEC, SW900, SK-MES-
1, SK-MEL-28 and Mel624. After defining uninfected samples
as steady state and filtering for significantly regulated genes (as
described in Materials & Methods), a correspondence analysis plot
was calculated in M-CHiPS. It simultaneously displays hybridiza-
tions (conditions, colored symbols) and genes (grey dots). The
relative position of conditions indicates their similarities or
differences. Conditions clustering closely together exhibit similar
gene expression patterns while conditions located opposite of the
centroid (0/0) exhibit substantial differences in gene expression.
Genes strongly associated with a condition are located in the same
direction from the centroid. Uninfected controls for all cell types
are clustering because of the normalization procedure. The plot
shows most substantial changes in cellular gene expression by
HAdV-5 infection for HBEC (highest distance to uninfected
control), followed by SW900 and SK-MES-1, but modest changes,
only, for SK-MEL-28 and Mel624.
(TIF)
Figure S4 Hierarchical clustering of HAdV-5-induced
gene expression in HBEC, SW900, SK-MES-1, SK-MEL-
28 and Mel624 reveals clusters with opposing regulation
in HBEC versus melanoma cells. Magnified clusters 1 and 2
from Fig. 3.
(TIF)
Figure S5 Validation of microarray data by qPCR. For a
set of 7 selected genes, qPCR quantification of mRNA was
performed. Concentrations of mRNAs were normalized to
concentrations of ACTB based on qgene and values for uninfected
HBEC were set to 1 to allow for comparison of qPCR and
microarray data. Scatter blots show correlation of log2 trans-
formed values from qPCR and microarray for uninfected cells
(upper panel) and infected cells (lower panel). The coefficient of
determination (R
2) was calculated for each cell line based on linear
trend curves with R
2=1 equaling 100%. Analysis of this low
number of genes already demonstrated a high correlation of qPCR
and microarray data for HBEC, SW900, SK-MES-1 and SK-
MEL-28. With this set of genes lower R
2 values were obtained for
Mel624.
(TIF)
Figure S6 Pathway analysis of HAdV-5 infection-in-
duced genes in HBEC versus SK-MEL-28. Expression
values were uploaded to the Ingenuity Pathway Analysis (IPA)
software and mapped onto the canonical G1/S transition
regulatory network of the cell cycle for HBEC and SK-MEL-28.
Green and red nodes represent down- and up-regulated genes,
respectively. Color intensity correlates with strength of fold
change.
(TIF)
Table S1 Infectious particle titers used to achieve 80%
tranduction efficiency for individual cell types as
determined by transduction with HAdV-5 CMV-gfp and
quantification of GFP positive cells in the living cell
fraction by fluorescence cytometry.
(DOC)
Table S2 Gene annotations and genes significantly
accumulating in the top 100 down-regulated genes in
HBEC.
(DOC)
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